Kepler Capital Remains a Buy on A2A SpA (0N54)
Elevate Your Investing Strategy:
Take advantage of TipRanks Premium at 50% off! Unlock powerful investing tools, advanced data, and expert analyst insights to help you invest with confidence.
Oggioni covers the Utilities sector, focusing on stocks such as Enel S.p.A., ACEA SPA, and A2A SpA. According to TipRanks, Oggioni has an average return of 2.9% and a 58.44% success rate on recommended stocks.
In addition to Kepler Capital , A2A SpA also received a Buy from TR | OpenAI – 4o's Watt Griddy in a report issued on July 24. However, on July 30, TR | OpenAI – 4o reiterated a Hold rating on A2A SpA (LSE: 0N54).
The company has a one-year high of €2.38 and a one-year low of €1.83. Currently, A2A SpA has an average volume of 705.3K.
Try Our AI Features
Explore what Daily8 AI can do for you:
Comments
No comments yet...
Related Articles
Business Wire
5 hours ago
- Business Wire
ViruSure launches pioneering first-in-class viral contamination test for biopharmaceuticals using Oxford Nanopore technology
OXFORD, England & VIENNA, Austria--(BUSINESS WIRE)--ViruSure, a global leader in pathogen safety testing for biopharmaceuticals, and Oxford Nanopore Technologies ('Oxford Nanopore') (LSE: ONT), the company behind a new generation of molecular sensing technology based on nanopores, today announce the launch of the industry's first Good Laboratory Practice (GLP) validated adventitious viral agent (AVA) detection test using nanopore-based sequencing technology. The ViruSure test has been developed and evaluated under rigorous conditions and is powered by Oxford Nanopore's advanced molecular sensing platform. It will be used for the detection of viral contamination within the manufacturing process, providing biopharmaceutical teams with richer viral detection insights and faster time-to-result, accessibly and affordably. A rapid and sensitive test, it can detect AVAs regardless of virus type, to improve confidence in biomanufacturing safety. Viral contamination remains one of the most significant threats to biopharmaceutical manufacturing, causing production delays and potential biologic, vaccine and cell and gene therapy product shortages. Traditional viral detection methods can take months to provide the full panel of results, with each individual test often taking more than 14 days, and contaminants still going undetected or reported as false positives. This innovation addresses a critical need to streamline AVA detection within biomanufacturing, a rapidly growing market currently valued at $20 billion, of which at least $4 billion is related to AVA testing. Global regulatory authorities have also recognised the urgent industry demand for faster and more reliable solutions and actively encouraged the adoption of advanced sequencing-based testing methods. i Dr Andy Bailey, CEO of ViruSure, commented: 'The development of this cutting-edge test for adventitious agents marks a major advancement in the industry's ability to detect a wide range of contaminants with exceptional sensitivity. Offering significantly improved specificity compared to traditional short-read next-generation sequencing methods, this innovation sets a new benchmark in virus detection. Powered by Oxford Nanopore technology, the test produces datasets with minimal background noise, greatly simplifying the identification of potential viral signals. This crucial feature supports biopharmaceutical manufacturers in achieving faster product evaluation and release, enhancing both safety and efficiency.' Gordon Sanghera, CEO Oxford Nanopore, commented: 'Contamination during the biomanufacturing process can pose considerable risks to patient safety, as well as production delays and drug shortages, which is not wanted by biopharmaceutical companies – nor the patients and health systems they serve. With the introduction of this first-in-class test, ViruSure is directly addressing the industry's critical demand for rapid, information-rich, and cost-effective viral detection methods, and we're proud to have played a key role in its development.' ViruSure and Oxford Nanopore are also working together to introduce a Good Manufacturing Process (GMP)-validated solution, which they expect will follow shortly. About ViruSure ViruSure, an Asahi Kasei Life Science company, is a leading global Contract Research Organization specializing in virus and prion biosafety testing for the biopharmaceutical and life science industries, with more than 20 years of experience. Located in Vienna, Austria, ViruSure partners with industry to support their quality control testing needs and ensure the safety and purity of biopharmaceuticals, cell & gene therapies, and vaccines. ViruSure is an integral part of the Biosafety Testing Services Unit of Asahi Kasei Life Sciences. To learn more about ViruSure, visit About Oxford Nanopore Technologies Oxford Nanopore Technologies' goal is to bring the widest benefits to society through enabling the analysis of anything, by anyone, anywhere. The company has developed a new generation of nanopore-based sensing technology for faster, information rich, accessible and affordable molecular analysis. The first application is DNA/RNA sequencing, and the technology is in development for the analysis of other types of molecules including proteins. The technology is used in more than 125 countries to understand and characterise the biology of humans and diseases such as cancer, plants, animals, bacteria, viruses, and whole environments. Oxford Nanopore Technologies products are intended for molecular biology applications and are not intended for diagnostic purposes. For more, visit:
Business Insider
6 hours ago
- Business Insider
U.S. Stock Futures Rise After President Trump Announces New Tariffs
U.S. stock futures inched higher Wednesday evening after President Donald Trump disclosed new tariffs on imported semiconductors and chips. Futures on the Nasdaq 100 (NDX), the Dow Jones Industrial Average (DJIA), and the S&P 500 Index (SPX) were up 0.16%, 0.07%, and 0.17%, respectively, at 7:04 p.m. EDT on August 6. Elevate Your Investing Strategy: Take advantage of TipRanks Premium at 50% off! Unlock powerful investing tools, advanced data, and expert analyst insights to help you invest with confidence. Trump stated that a 100% tariff would be applied to imported chips, but with a key exemption: companies that are 'building in the United States' would not be subject to the new levy. This news came shortly after Apple (AAPL) committed an additional $100 billion investment in the U.S. over the next four years. This follows a positive day for the broader market, with the S&P 500, the Nasdaq Composite, and the Dow gaining 0.7%, 1.2%, and 0.2%. Traders continue to monitor tariff-related news and key quarterly earnings reports. Looking ahead to Thursday, traders are focused on new economic data, including Weekly Jobless Claims, as well as the second-quarter reports on Unit Labor Costs and Productivity. On the corporate earnings front, SoundHound AI (SOUN), D-Wave Quantum (QBTS), Pinterest (PINS), Block (XYZ), and Eli Lilly (LLY) are scheduled to release quarterly numbers.
Business Insider
6 hours ago
- Business Insider
Apple Stock (AAPL) Surges on New $100B U.S. Investment Drive
Shares in U.S. tech giant Apple (AAPL) rose 4% in early trading after the White House said it was planning to announce a new huge production investment in the U.S. later today. Elevate Your Investing Strategy: Take advantage of TipRanks Premium at 50% off! Unlock powerful investing tools, advanced data, and expert analyst insights to help you invest with confidence. According to White House spokesperson Taylor Rogers, President Donald Trump will announce that Apple will commit to spend another $100 billion on domestic manufacturing. New Manufacturing Program Trump, with Apple chief executive officer Tim Cook also likely to attend, will reveal that the spend will include a new manufacturing program designed to bring more of Apple's supply chain to the US, with an eye toward manufacturing additional critical components domestically. 'President Trump's America First economic agenda has secured trillions of dollars in investments that support American jobs and bolster American businesses,' White House spokesperson Taylor Rogers said in a statement. 'Today's announcement with Apple is another win for our manufacturing industry that will simultaneously help reshore the production of critical components to protect America's economic and national security.' Apple did not immediately respond to media requests for comment. The company has previously announced it plans to spend $500 billion in the US over the next four years, which will include work on a new server manufacturing facility in Houston, a supplier academy in Michigan and additional spending with its existing suppliers in the country. Today's announcement will bring Apple's cumulative commitment to $600 billion, the White House said. Apple Options Although Trump will likely paint the investment as another win for his tariffs policy, which partly are based on ramping up U.S. production, it will still fall short of its goals to see a full shift of Apple manufacturing. Earlier this year, the president threatened to hit Apple with a tariff of at least 25% if it didn't move manufacturing of the iPhone to the US, a day after meeting with Cook at the White House. It has been looking at upping its supply from other countries instead, such as India. Apple revealed last week that it took an $800 million hit from tariffs in the June quarter and expected them to add $1.1 billion to its costs in the September quarter, assuming no policy changes or new duties. The uncertainty has been weighing on Apple's stock this year. Is AAPL a Good Stock to Buy Now? On TipRanks, AAPL has a Moderate Buy consensus based on 14 Buy, 12 Hold and 1 Sell ratings. Its highest price target is $275. AAPL stock's consensus price target is $233.33, implying a 14.74% upside.
